marketshareAI
Theme

Aptamer Group

APTAHealthcare
0.8500GBX
6.25%
Market Cap
22.92M
Volume
700.3k
7% of avg
P/E Ratio
NaN
EPS (TTM)
Beta
0.71
Day Range
0.7500p - 0.8500p
52 Week Range
0.2310p0.8500p1.5700p
0.8500p

Upcoming Events

31 December 2025
Potential initial trials by UK water companies
High Impact Event
January 2026
Anticipated commercialization of Optimer-containing vaccines
High Impact Event
Early Q1 2026
Q1 2026 trading update
High Impact Event
FY2026
Delivery of £1.95 million order book
High Impact Event
March 2026
Completion of current contract portfolio
High Impact Event
Q2 2026
Invizius' H-Guard® technology entering Phase 2 clinical trials
High Impact Event
Mid-2026
Prototype ELISA assay development and validation expected to be completed
High Impact Event
2027
First commercial sales of Alzheimer's disease diagnostic test
High Impact Event
Early 2030
Estimated global market for fibrosis treatments to exceed $20 billion
High Impact Event
APTA
NEUTRAL

Aptamer Group Provides AGM Update

The leading developer of synthetic binders provides an update on its recent commercial progress and strategic positioning.

APTA
VERY GOOD

Aptamer Group Secures £1.95 Million in New Contracts with Top Pharmaceutical Partners

The biotechnology company has secured £1.95 million in new contracts with major pharmaceutical partners, demonstrating strong commercial momentum and validation of its proprietary technology platform.

APTA
VERY GOOD

Aptamer Group secures major repeat business with top 5 pharma partner

The developer of next-generation synthetic binders has secured a major new contract with a top 5 pharmaceutical company, worth up to £617,000. This repeat business validates the company's Optimer® platform and provides strong revenue visibility.

APTA
NEUTRAL

Aptamer Group Publishes Annual Report and AGM Notice

The biotechnology company has published its annual report and notice of the upcoming annual general meeting.

APTA
NEUTRAL

Aptamer Group Reports 40% Revenue Growth in Full Year Results

The biotechnology firm reported a 40% increase in revenue and expanded its licensable asset portfolio. However, it continues to operate at a loss and faces ongoing funding challenges.

APTA
GOOD

Aptamer Group Secures £112,000 Contract with Top 10 Pharma

The developer of next-generation synthetic binders secures a £112,000 contract with a top 10 global pharmaceutical company, building on recent commercial progress and diversifying revenue streams.

APTA
NEUTRAL

Aptamer Group Announces Full Year Results Presentation

The biotechnology company will announce its full year results and hold an analyst briefing and investor presentation.

APTA
GOOD

Aptamer Group Secures Major Pharmaceutical Contract for Radiopharmaceutical Development

The biotechnology company has secured a major new contract with a top 3 global pharmaceutical firm to develop targeted radiopharmaceuticals, representing a significant expansion of its Optimer platform technology.

APTA
NEUTRAL

Aptamer Group to Present at ShareSoc Growth Company Seminar

The biotechnology company will be presenting at an investor event, offering an opportunity for direct engagement with investors.

APTA
GOOD

Aptamer Group signs new contract with Metir for pathogen detection platform

The biotechnology company has signed a new contract with a leading provider of water and environmental testing technology to develop its Optimer® binders for a pathogen detection platform.